CREST Data To Support Abbott’s Bid For Expanded Carotid Stent Labeling
This article was originally published in The Gray Sheet
Executive Summary
Abbott will use data from the large CREST trial to seek an FDA panel recommendation this week in favor of significantly expanding its labeling for the RX Acculink carotid stent system to address more patients at risk for stroke.
You may also be interested in...
FDA Panel Leans In Favor Of Expanded Indication For Abbott’s Carotid Stent
An FDA advisory panel provided support for Abbott's bid to expand labeling for its RX Acculink carotid stent system to treat a larger patient population, despite reservations from some members about safety.
FDA Panel Leans In Favor Of Expanded Indication For Abbott’s Carotid Stent
An FDA advisory panel provided support for Abbott's bid to expand labeling for its RX Acculink carotid stent system to treat a larger patient population, despite reservations from some members about safety.
Blues' TEC Delivers Negative Assessment On Carotid Stenting
A recent negative BlueCross BlueShield Association technology assessment could be another barrier to expanded coverage of carotid stenting